ArticleEJNMMI research2026
Biodistribution and dosimetry of the carbon-11 labelled PARP1-selective PET radiopharmaceutical [
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoly (ADP-ribose) polymerase-1 (PARP1) inhibitors are used for treatment of advanced breast, ovarian, and prostate cancer with germline or somatic BRCA1/2 mutations. However, not all patients respond to these drugs, and therapy-predictive biomarkers are needed to optimise the benefit-risk balance. The
resultsTen participants (5 breast, 3 ovarian, 2 prostate cancer) were injected with 5.7 MBq/kg [
conclusionsImaging with [ CLINICAL TRIAL REGISTRY: Ongoing recruitment Human Pharmacology (phase I) trial in Sweden including cancer patients in the age range (18-64) years. SPONSOR: Karolinska University Hospital. https://euclinicaltrials.eu/ctis-public/view/2022-502918-87-00 : Registry identifier: EU CT 2022-502918-87-00; Date of registration: 2023-08-17.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.